Physiomics (PYC.L) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $800K

Market Cap: $3.3MFounded: 2001Employees: 11-50HQ: Oxford, United Kingdom

Sector Ranking#43 in AI / Machine Learning #100 in Digital Health & Biotech SaaS

Overview

Physiomics is a specialized, data-driven consultancy focused on Model-Informed Drug Development (MIDD) for oncology. Its mission is to improve the success rate and reduce the cost/time of drug development through advanced quantitative modeling, biostatistics, and bioinformatics. The company has validated its proprietary Virtual Tumour™ technology across over 70 projects, modeling more than 125 targets and drugs, and has built a diversified client base that includes Servier, Bicycle Therapeutics, and Numab Therapeutics. Its strategy centers on being an essential, capital-light service partner in the high-growth computational biology and pharmacometrics space.

OncologyInflammatory Disease

Technology Platform

Proprietary 'Virtual Tumour™' platform, a semi-mechanistic Quantitative Systems Pharmacology (QSP) model that simulates tumor growth and the effects of drug combinations, integrated with industry-standard modeling, biostatistics, and bioinformatics capabilities.

Funding History

2

Total raised:$800K

Grant$300KEuropean UnionJul 15, 2019

Grant$500KInnovate UKMar 15, 2018

Opportunities

The company is positioned at the convergence of rising regulatory adoption of Model-Informed Drug Development (MIDD), increasing complexity in oncology R&D (especially combination therapies), and the growth of biotechs outsourcing quantitative expertise.

This creates a significant market for its validated, oncology-specific modeling platform and services.

Risk Factors

Key risks include dependency on a continuous stream of client projects and potential client concentration, competition from larger CROs and specialist boutiques, reliance on key scientific personnel, and the challenges of being a small-cap stock on the AIM market with associated liquidity and volatility issues.

Competitive Landscape

Physiomics competes with large, full-service CROs (e.g., IQVIA) on specialization and with smaller modeling boutiques on track record and platform sophistication. Its primary differentiators are its long-standing, validated Virtual Tumour™ platform focused exclusively on oncology and its deep team expertise, as evidenced by over 70 completed projects and strong client testimonials.